[Curative effect analysis of ipsilateral total knee and hip arthroplasty at stage I].

Objective: To explore clinical results of ipsilateral total knee and hip arthroplasty at stage I for the treatment of ipsilateral hip and knee diseases.
Methods: From January 2008 to September 2016, 7 patients with ipsilateral knee and hip disease were treated by simultaneous total knee and hip arthroplasty at stage I, including 4 males and 3 females aged from 47 to 68 years old, the courses of disease ranged from 6 to 29 years; 3 patients with rheumatoid arthritis, 3 patients with ankylosing spondylitis, and 1 patient with senile hip and knee arthritis. Operation time, intraoperative blood loss and local wounds during hospitalization were observed and recorded, and Harris hip score and HSS knee score were used to evaluate therapeutic effects.
Results: Seven patients were followed up from 6 to 24 months, operative time ranged from 297 to 362 min, blood loss ranged from 300 to 780 ml. Harris hip score before operation ranged from 27.67 to 39.11, 75.32 to 85.10 at 6 months after operation; 3 patients were good and 4 patients moderate. HSS knee score before operation ranged from 40.90 to 51.36, and 73.56 to 85.33 at 6 months after operation; 1 patients were excellent and 6 patients good. No periprosthetic fracture, aseptic loosening and periprosthetic infection occurred in 7 patients.
Conclusions: Ipsilateral total knee and hip arthroplasty at stage I for the treatment of hip and knee disease could restore hip and knee function as soon as possible and recover function of hip and knee to the maximum degree, make patients get down the bed earlier, effectively reduce the complications caused by long-term bedridden, and improve patient's quality and satisfaction of life. While the quality of double-joint arthroplasty at stage I need higher technical requirements which should strengthen the management of the perioperative period, and strictly grasped indications.
Competing Interests: The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
(Copyright© 2019 by the China Journal of Orthopaedics and Traumatology Press.)